iqvia semaglutide tirzepatide prescriptions us q3 2024 GLP-1 prescription trends through June Obesity Deep Dive: The Unparalleled

Dose Group GI Adverse Events (%) Nausea (%) Abdominal Discomfort/Pain Placebo 32.6% 11.6% Low baseline 1 mg 48.6% ~20% Mild, infrequent 4 mg (escalated) 60.0% ~30% Moderate increase 8 mg (escalated) 57.5% ~38% Present in dose-escalation phase 12 mg (escalated) 66.7% 45.8% Highest incidence, mostly transient Source: Jastreboff AM, Kaplan LM, Fras JP, et al

Reports can be submitted online via the Yellow Card website ( through the Yellow Card app, or by completing a paper form

Driven by high demand and increased production, Q4 2025 revenue alone hit $4.3 billion, serving as a key driver of Eli Lillys 2025 growth.

Dai J, Xie Y, Wu Q, et al

Advanced diagnostics guide all plans, ensuring precision